Baudax Bio Management
Management criteria checks 3/4
Baudax Bio's CEO is Gerri Henwood, appointed in Nov 2019, has a tenure of 4.42 years. total yearly compensation is $663.22K, comprised of 93.2% salary and 6.8% bonuses, including company stock and options. directly owns 0.004% of the company’s shares, worth $21.56. The average tenure of the management team and the board of directors is 0.5 years and 4.4 years respectively.
Key information
Gerri Henwood
Chief executive officer
US$663.2k
Total compensation
| CEO salary percentage | 93.2% |
| CEO tenure | 4.4yrs |
| CEO ownership | 0.004% |
| Management average tenure | less than a year |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Baudax Bio stock down after pricing $6.2M equity offering
Aug 30Baudax Bio to get US patent linked to pain drug Anjeso
Aug 22Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M
Aug 11Cosette Pharmaceuticals appoints Rick Casten as CFO
Jul 06Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds
Sep 09A First Look At Baudax Bio
May 30Baudax Bio EPS misses by $0.08, misses on revenue
May 05Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty
Apr 26Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?
Feb 17
Baudax Bio EPS of $0.62
Nov 09Baudax Bio: Why I'm Catching This Falling Knife
Nov 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$58m |
| Dec 31 2022 | US$663k | US$618k | -US$59m |
| Sep 30 2022 | n/a | n/a | US$13m |
| Jun 30 2022 | n/a | n/a | -US$67k |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$2m | US$618k | -US$20m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$38m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$603k | US$309k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$66m |
| Jun 30 2020 | n/a | n/a | -US$88m |
| Mar 31 2020 | n/a | n/a | -US$69m |
| Dec 31 2019 | US$3m | US$46k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$51m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$2m | US$599k | -US$74m |
Compensation vs Market: Gerri's total compensation ($USD663.22K) is about average for companies of similar size in the US market ($USD668.06K).
Compensation vs Earnings: Gerri's compensation has been consistent with company performance over the past year.
CEO
Gerri Henwood (71 yo)
4.4yrs
Tenure
US$663,224
Compensation
Dr. Geraldine A. Henwood, also known as Gerri, Ph D., has been the President, Chief Executive Officer and Director of Baudax Bio Inc. since 2019. She has been the Chief Development Officer of Iomab-B at Ac...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.4yrs | US$663.22k | 0.0037% $ 21.6 | |
| Vice President of Financial Planning & Analysis | less than a year | no data | no data | |
| Consultant & Principle Accounting Officer | less than a year | no data | no data | |
| Chief Scientific Officer & Director | less than a year | no data | no data |
0.5yrs
Average Tenure
52yo
Average Age
Experienced Management: BXRX.Q's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.4yrs | US$663.22k | 0.0037% $ 21.6 | |
| Chief Scientific Officer & Director | less than a year | no data | no data | |
| Independent Director | 4.4yrs | US$95.11k | 0.0022% $ 13.1 | |
| Independent Chairman | 5.3yrs | US$113.59k | 0.0020% $ 12.0 | |
| Independent Director | 3.7yrs | US$89.97k | 0.0020% $ 11.6 | |
| Independent Director | 5.3yrs | US$99.97k | 0.0020% $ 11.9 | |
| Independent Director | 3.7yrs | US$82.47k | 0.0020% $ 11.8 |
4.4yrs
Average Tenure
71yo
Average Age
Experienced Board: BXRX.Q's board of directors are considered experienced (4.4 years average tenure).